文献速递炎症性肠病

乌帕替尼治疗克罗恩病的真实世界有效性与安全性:一项多中心研究

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-03-08

这项在美国9个中心开展的回顾性分析纳入334例接受乌帕替尼45 mg诱导治疗的成人克罗恩病患者,12周临床缓解率为52.1%,6个月临床缓解率为55.9%,6个月内镜缓解率为42.7%,13.5%报告不良事件,19.1%停用乌帕替尼,未发现新的安全性问题。

要点

  • 乌帕替尼45 mg诱导治疗12周临床缓解率52.1%,6个月临床缓解率55.9%。
  • 6个月内镜缓解率为42.7%,既往先进治疗暴露次数越多缓解比例越低。
  • 不良事件报告率13.5%,19.1%停用乌帕替尼,未发现新的安全性问题。

核心结论

  • 乌帕替尼在真实世界克罗恩病患者中能有效诱导临床和内镜缓解,即使既往暴露于多种先进治疗亦如此,且未发现新的安全性问题。

研究设计与样本

  • 回顾性分析,覆盖美国9个中心,纳入接受乌帕替尼45 mg诱导治疗活动性管腔疾病的成人克罗恩病患者334例(中位年龄34岁,病程12年,44.6%为女性)。

主要发现

  • 12周临床缓解率为52.1%,6个月临床缓解率为55.9%,6个月内镜缓解率为42.7%。
  • 12周临床缓解率:先进治疗初治患者58.6%,1种既往先进治疗者53.3%,2种及以上既往先进治疗者50.2%。
  • 6个月临床缓解率:先进治疗初治患者97.7%,1种既往先进治疗者66.7%,2种及以上既往先进治疗者40.5%。
  • 体重指数和较长病程与12周临床缓解的较低几率相关。
  • 不良事件报告率为13.5%,19.1%的患者停用乌帕替尼。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor, in patients with Crohn's disease (CD). METHODS: A retrospective analysis was conducted across 9 centers in the United States, focusing on adults with CD treated with UPA, 45 mg, as induction therapy for active luminal disease. The coprimary end points were clinical remission at 12 weeks (Harvey Bradshaw Index ≤4 or absence of symptoms on physician's global assessment) and endoscopic remission at 6 months (Simplified Endoscopic Mucosal Assessment for Crohn's Disease score of 0-1 or absence of ulcers). Secondary outcomes included clinical, radiographic, and histologic outcomes, and adverse events. RESULTS: The study included 334 patients with CD (median age, 34 years; disease duration, 12 years; 44.6% female). Clinical remission was achieved in 52.1% at 12 weeks and 55.9% at 6 months. Endoscopic remission at 6 months was observed in 42.7% of patients. Advanced therapy-naive patients achieved a higher proportion of clinical remission at 12 weeks (58.6%) and 6 months (97.7%) compared with patients with 1 prior advanced therapy (53.3% and 66.7%) and 2 or more prior advanced therapy exposures (50.2% and 40.5%), respectively. Body mass index and longer disease duration was associated with lower odds of clinical remission at 12 weeks. Adverse events were reported in 13.5% and UPA discontinued in 19.1%. CONCLUSIONS: UPA was effective at inducing clinical and endoscopic remission in a real-world group of patients with CD, even with prior exposure to multiple prior advanced therapies. No new safety concerns were identified.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Devi J, Xu A, Stone M, et al. Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study. Clin Gastroenterol Hepatol. 2025. PMID: 40058746. doi:10.1016/j.cgh.2025.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。